What is Swedish Orphan Biovitrum AB Pre-Tax Income?
Pretax income is the income that a company earns before paying income taxes. Swedish Orphan Biovitrum AB's pretax income for the
three
months ended in Mar. 2024 was kr982 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Mar. 2024 was kr2,610 Mil.
Swedish Orphan Biovitrum AB's pretax margin was 15.70%.
During the past 13 years, Swedish Orphan Biovitrum AB's highest Pretax Margin was 33.72%. The lowest was -12.22%. And the median was 20.68%.
Swedish Orphan Biovitrum AB Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Swedish Orphan Biovitrum AB's Pre-Tax Income
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB's Pre-Tax Income Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Pre-Tax Income falls into.
Swedish Orphan Biovitrum AB Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr2,610 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (OSTO:SOBI) Pre-Tax Income Explanation
Swedish Orphan Biovitrum AB's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, Swedish Orphan Biovitrum AB's highest Pretax Margin was 33.72%. The lowest was -12.22%. And the median was 20.68%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Swedish Orphan Biovitrum AB (OSTO:SOBI) Business Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:SOBI has been successfully added to your 